Cargando…

Novel selective β(1)-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

β-Blockers reduce mortality and improve symptoms in people with heart disease; however, current clinically available β-blockers have poor selectivity for the cardiac β(1)-adrenoceptor (AR) over the lung β(2)-AR. Unwanted β(2)-blockade risks causing life-threatening bronchospasm and reduced efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Jillian G., Gardiner, Sheila M., Woolard, Jeanette, Fromont, Christophe, Jadhav, Gopal P., Mistry, Shailesh N., Thompson, Kevin S. J., Kellam, Barrie, Hill, Stephen J., Fischer, Peter M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Federation of American Societies for Experimental Biology 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471521/ https://www.ncbi.nlm.nih.gov/pubmed/28400472 http://dx.doi.org/10.1096/fj.201601305R

Ejemplares similares

Synthesis and in Vitro and in Vivo Characterization of Highly β(1)-Selective β-Adrenoceptor Partial Agonists
por: Mistry, Shailesh N., et al.
Publicado: (2013)

Synthesis and Characterization of High-Affinity 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors
por: Baker, Jillian G., et al.
Publicado: (2011)

Subtype selective fluorescent ligands based on ICI 118,551 to study the human β2‐adrenoceptor in CRISPR/Cas9 genome‐edited HEK293T cells at low expression levels
por: Goulding, Joëlle, et al.
Publicado: (2021)

NanoBiT Complementation to Monitor Agonist-Induced Adenosine A(1) Receptor Internalization
por: Soave, Mark, et al.
Publicado: (2019)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G.W., et al.
Publicado: (2022)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2020)

27th Annual GP2A Medicinal Chemistry Conference
por: Mistry, Shailesh N., et al.
Publicado: (2019)

Involvement of β‐adrenoceptors in the cardiovascular responses induced by selective adenosine A(2A) and A(2B) receptor agonists
por: Wragg, Edward S., et al.
Publicado: (2022)

A monoclonal antibody raised against a thermo-stabilised β(1)-adrenoceptor interacts with extracellular loop 2 and acts as a negative allosteric modulator of a sub-set of β(1)-adrenoceptors expressed in stable cell lines
por: Soave, Mark, et al.
Publicado: (2018)

A Full Pharmacological Analysis of the Three Turkey β-Adrenoceptors and Comparison with the Human β-Adrenoceptors
por: Baker, Jillian G.
Publicado: (2010)

Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies
por: Soave, Mark, et al.
Publicado: (2020)

Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET
por: Alcobia, Diana C., et al.
Publicado: (2018)

Negative cooperativity across β(1)-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation
por: Gherbi, Karolina, et al.
Publicado: (2015)

Use of a new proximity assay (NanoBRET) to investigate the ligand‐binding characteristics of three fluorescent ligands to the human β (1)‐adrenoceptor expressed in HEK‐293 cells
por: Soave, Mark, et al.
Publicado: (2016)

The signaling and selectivity of α‐adrenoceptor agonists for the human α2A, α2B and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2022)

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2021)

Complex Formation between VEGFR2 and the β(2)-Adrenoceptor
por: Kilpatrick, Laura E., et al.
Publicado: (2019)

Impact of Polymorphic Variants on the Molecular Pharmacology of the Two-Agonist Conformations of the Human β1-Adrenoceptor
por: Baker, Jillian G., et al.
Publicado: (2013)

Kinetic analysis of antagonist-occupied adenosine-A(3) receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism
por: Corriden, Ross, et al.
Publicado: (2014)

Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

β(1) Adrenoceptor antagonistic effects of the supposedly selective β(2) adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts
por: Pecha, Simon, et al.
Publicado: (2015)

Use of α1‐adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease
por: Latvala, Laura, et al.
Publicado: (2022)

Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A(1) receptor ligands
por: Baker, Jillian G, et al.
Publicado: (2010)

The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers
por: Batty, Mallory, et al.
Publicado: (2016)

Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H(1) Receptor
por: Kok, Zhi Yuan, et al.
Publicado: (2022)

"Ejaculatory disorders and α(1)-adrenoceptor antagonists therapy: clinical and experimental researches"
por: Grasso, Marco, et al.
Publicado: (2006)

Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
por: Takara, Kohji, et al.
Publicado: (2012)

Chemically Homogenous Compounds with Antagonistic Properties at All α(1)-Adrenoceptor Subtypes but not β(1)-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

Ligand-directed covalent labelling of a GPCR with a fluorescent tag in live cells
por: Stoddart, Leigh A., et al.
Publicado: (2020)

Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y(2) Receptor Based on AR-C118925
por: Conroy, Sean, et al.
Publicado: (2018)

Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates
por: Baker, Jillian G., et al.
Publicado: (2007)

Correction to Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y(2) Receptor Based on AR-C118925
por: Conroy, Sean, et al.
Publicado: (2018)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease()
por: Dale, Philippa R, et al.
Publicado: (2014)

The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum
por: Wuest, Melinda, et al.
Publicado: (2011)

The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P
por: Fuchs, Robert, et al.
Publicado: (2015)

Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36
por: Bhatt, Lokesh K, et al.
Publicado: (2010)

Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016)

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
por: Shimizu, Shogo, et al.
Publicado: (2015)

Propranolol, a β-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis
por: McKee, Chad, et al.
Publicado: (2013)

Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil
por: Tanuma, Yasushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5ssmp1v46ad0mkfit01v1c7ldt